Abstract |
The results of a multicentre, double-blind trial are reported, where the effectiveness and safety of indoprofen (IP) were compared with indomethacin (IM) and placebo (PL), in patients with rheumatoid arthritis. After an initial "wash-out" period (3 days), each patient was given each of the three treatments for one week, in randomized sequence. The total dose of indoprofen ( tablets) was 800 mg/die and that of indomethacin (capsules) 200 mg/die, in 4 daily doses after the main meals. The evaluation of effectiveness on a cumulative group of 102 cases from 18 centres showed statistically significant differences in favour of both active drugs compared to placebo, based on a series of objectives and subjective criteria. There was no significant difference between IP and IM, but on factorial analysis of correspondences, IP showed a greater difference from placebo. The patient's judgments also suggested that IP (800 mg/die) was slightly more effective than IM (100 mg/die). Adverse reactions were observed in 8.9% of the patients on IM treatment, 3.9% on IP and in 39% on PL. Laboratory variables showed no significant changes in the course of treatment.
|
Authors | F Delbarre |
Journal | European journal of rheumatology and inflammation
(Eur J Rheumatol Inflamm)
Vol. 4
Issue 1
Pg. 66-73
( 1981)
ISSN: 0140-1610 [Print] England |
PMID | 7042364
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Phenylpropionates
- Placebos
- Indoprofen
- Indomethacin
|
Topics |
- Adult
- Aged
- Analysis of Variance
- Arthritis, Rheumatoid
(drug therapy)
- Clinical Trials as Topic
- Double-Blind Method
- Female
- Humans
- Indomethacin
(therapeutic use)
- Indoprofen
(therapeutic use)
- Male
- Middle Aged
- Phenylpropionates
(therapeutic use)
- Placebos
- Random Allocation
|